Journal of pain and symptom management
-
J Pain Symptom Manage · Feb 2021
ReviewEffect of virtual reality therapy in reducing pain and anxiety for cancer related medical procedures: A systematic narrative review.
Virtual reality (VR) has emerged as a novel form of nonpharmacological analgesia therapy. We wished to review the use of VR to treat pain and anxiety in cancer-related medical procedures and chemotherapy. ⋯ There is inconclusive evidence on the significance of immersive VR in reducing pain (five studies) or anxiety (six studies) for patients with cancer undergoing medical interventions or receiving chemotherapy. Further research on the effect of immersive VR as a tool for medical procedures and/or patients with cancer undergoing treatment is required.
-
J Pain Symptom Manage · Feb 2021
ReviewExploring Factors Associated with Long-Term Opioid Therapy in Cancer Survivors:An Integrative Review.
The prevalence of chronic pain in cancer survivors is double that of the general U.S. ⋯ The studies in this review shed light on the factors associated with LTOT in cancer survivors. LTOT was common in certain populations of cancer survivors and those with a collection of patient-specific characteristics. This review suggests that there is a critical need for specialized research on chronic cancer pain and opioid safety in cancer survivors.
-
J Pain Symptom Manage · Feb 2021
National Trends in Hospice Facility Deaths in the United States, 2003-2017.
Hospice facilities are increasingly preferred as a location of death, but little is known about the characteristics of patients who die in these facilities in the U.S. ⋯ Hospice facility deaths increased among all patient groups; however, striking differences exist by age, sex, race, marital status, education level, cause of death, and geography. Factors underlying these disparities should be examined.
-
J Pain Symptom Manage · Feb 2021
Randomized Controlled Trial Pragmatic Clinical TrialElectro-acupuncture for post-stroke spasticity: results of a pilot pragmatic randomized controlled trial.
People with spasticity that occurred between 30 days and one year after stroke onset with a baseline Modified Ashworth Scale (MAS) ≥1. ⋯ It is feasible to conduct a full-scale trial to precisely evaluate the effectiveness and safety of EA for treating poststroke spasticity; however, longer treatment and follow-up phases should be considered in the full-scale trial.
-
J Pain Symptom Manage · Feb 2021
Randomized Controlled TrialNephrologist views regarding cannabinoid use in advanced chronic kidney disease and dialysis: a survey.
The efficacy and safety of cannabinoids to treat symptoms in individuals with kidney disease is uncertain. ⋯ Nephrologists broadly support the use and study of cannabinoids for symptoms in patients with kidney disease.